List view / Grid view
Production of protein therapeutics by mammalian cells is the most widely used bioprocess because of its ability to properly produce and fold a recombinant protein...
Scientists from Thermo Fisher Scientific discuss how the CaptureSelect affinity purification products and analytical tools have been developed for the discovery and manufacturing of therapeutic antibodies, including novel formats such as bi-specific antibodies and Fc-fusion proteins...
Subvisible particles in protein-based formulations can have different origins. Particles can be extrinsic (unexpected foreign material), intrinsic (from the production environment or primary packaging), and inherent (from the formulation). It is important that inherent particles (protein agglomerates) are distinguished from the other two types and that the extrinsic and intrinsic…
9 May 2017 | By University of Leeds
Data from a new device demonstrates maximal levels of extensional flow which manufacturers could use for different processes, without damaging proteins...
Biological products, usually referred to as biologics, constitute a significant segment of pharmaceuticals in development. Biologics include therapeutic proteins, antibody drugs, antibody-drug conjugates (ADCs), vaccines, carbohydrates drugs, blood and tissue-derived pharmaceuticals, gene therapies, even live cells and tissues...
The Thermo Fisher Scientific™ global bio/pharma tour is an opportunity to collaborate and network directly with experts in technology innovation...
24 February 2016 | By Tecan
The ARNA Laboratory in Bordeaux, France, is using DNA and RNA aptamers to develop novel tools for biological applications...
Life scientists who work with DNA, RNA and proteins can make educated decisions about sample suitability in experiments using a standalone, microvolume spectrophotometer for accurate quantitation and purity measurements to ensure downstream application success.
16 October 2015 | By CHI
Largest European Event for Biologics Returns to Lisbon from 2-6 November...
During early stage drug development, quickly obtaining relevant candidate proteins through transient transfection can accelerate drug discovery.
12 August 2015 | By Sartorius
Redesigned Sartobind® membrane adsorber capsules offer higher binding capacities, reduced void volumes, less buffer consumption and lower operational costs...
8 May 2015 | By Victoria White
Eleven Biotherapeutics presented clinical data for EBI-005 for dry eye disease and allergic conjunctivitis at the ARVO 2015 Annual Meeting...
28 October 2014 | By Rick Davies, Associate Director, AstraZeneca / Ian Hardern, Senior Research Scientist, AstraZeneca / Ross Overman, Associate Principal Scientist, AstraZeneca
Recombinant protein production is a prerequisite and essential component of most modern small molecule drug discovery programs. Target proteins are required to underpin screening, structural and mechanistic studies providing data that drives chemical design. From the initial establishment of recombinant protein production in the pharmaceutical industry in the 1980s, systems…
In Issue #4 2014: Protein Expression, Multivariate Data Analysis, Informatics in-depth focus, Particle Sizing, Lean Manufacturing, NIR In-depth focus, X-Ray Fluorescence and much more...
Lonza, a leader in biological development and BaroFold, Inc., an innovative protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold’s PreEMT™ high pressure refolding technology for use in biological development refolding processes.
